Ukrainian Journal Health of Woman. 2026. 2(183): 27-38. doi: 10.15574/HW.2026.2(183).2738
Chernov А. V., Serbeniuk А. V.
Shupyk National Healthcare University of Ukraine, Kyiv

For citation: Chernov АV, Serbeniuk АV. (2026). Clinical and anamnestic factors, risk profiles, obstetric and perinatal outcomes depending on the clinical phenotype of preeclampsia in women giving birth for the first time. Ukrainian Journal Health of Woman. 2(183): 27-38. doi: 10.15574/HW.2026.2(183).2738
Article received: Dec 21, 2025. Accepted for publication: Mar 22, 2026.

Different clinical phenotypes of preeclampsia (PE) are characterized by different risk factor profiles. Currently, it is not enough to develop treatment standards, it is necessary to assess the risk of PE for a particular patient and adjust the tactics of prediction and prevention depending on the results obtained.
Aim – to study clinical and anamnestic factors, risk profiles, obstetric and perinatal outcomes depending on the clinical phenotype of PE in women giving birth for the first time to develop an algorithm for predicting and stratifying the risk of its development.
Materials and methods. 937 pregnant women giving birth for the first time were examined: 101 (10.8%) pregnant women formed the group with PE, the control group consisted of 836 (89.2%) pregnant women with a physiological course of pregnancy. Data on maternal history, risk factors for PE development, blood pressure, Doppler, uterine artery pulsatility index, levels of free human chorionic gonadotropin, placental protein (PAPP-A), placental growth factor (PlGF), soluble tyrosine kinase -1 (sFlt-1), and the sFlt-1/PlGF ratio, measured in the first trimester, were recorded.
Results. Analysis of clinical, anamnestic and laboratory data demonstrated that in the PE group, the presence of chronic arterial hypertension in the anamnesis was 2.1 times more common, diabetes mellitus in the anamnesis – 5.5 times, kidney disease – 2.6 times, autoimmune diseases – 3.8 times, coagulation disorders – 3.3 times. The occurrence of pregnancy in this group was significantly more frequent by 1.7 times as a result of the use of in vitro fertilization. A significant decrease in PAPP-A and PlGF indicators and an increase in the sFlt-1/PlGF ratio in the group of pregnant women with PE. The highest risk among all profiles was given by the PE phenotype with fetal growth retardation (FGR).
Conclusions. Classification of PE based on phenotype with placental-fetal manifestations (with/without FGR) compared to a purely temporal classification (early/late – 34 weeks, preterm/term – 37 weeks) provides a better understanding of the etiological factors and mechanisms associated with PE.
The study was conducted in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained from the women for the study.
The authors declare no conflict of interest.
Keywords: pregnancy in primiparous women, preeclampsia, clinical and anamnestic risk factors, preeclampsia phenotypes, early preeclampsia, late preeclampsia, prediction of preeclampsia, risk stratification.

REFERENCES

1. American College of Obstetricians and Gynecologists. (2020). Gestational hypertension and preeclampsia. ACOG Practice Bulletin No. 222. Obstet Gynecol. 135(6): e237-e260. https://doi.org/10.1097/AOG.0000000000003891; PMid:32443079 PMCid:PMC8907436

2. Bhide A, Acharya G, Baschat A, Bilardo CM, Brezinka C, Cafici D et al. (2021). ISUOG Practice Guidelines (updated): use of Doppler velocimetry in obstetrics. Ultrasound Obstet Gynecol. 58(2): 331-339. https://doi.org/10.1002/uog.23698; PMid:34278615

3. Bilardo CM, Chaoui R, Hyett JA, Kagan KO, Karim JN, Papageorghiou AT et al. (2023). ISUOG Practice Guidelines (updated): performance of 11-14-week ultrasound scan. Ultrasound Obstet Gynecol. 61(1): 127-143. https://doi.org/10.1002/uog.26106; PMid:36594739 PMCid:PMC10152315

4. Burton GJ, Redman CW, Roberts JM, Moffett A. (2019, Jul 15). Pre-eclampsia: pathophysiology and clinical implications. BMJ. 366: l2381. https://doi.org/10.1136/bmj.l2381; PMid:31307997 PMCid:PMC12042644

5. Chappell LC, Cluver CA, Kingdom J, Tong S. (2021). Pre-eclampsia. Lancet. 398(10297): 341-354. https://doi.org/10.1016/S0140-6736(20)32335-7; PMid:34051884

6. Crovetto F, Figueras F, Triunfo S, Crispi F, Rodriguez-Sureda V, Dominguez C et al. (2015). First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors. Prenat Diagn. 35(2): 183-191. https://doi.org/10.1002/pd.4519; PMid:25346181

7. Dimitriadis E, Rolnik DL, Zhou W et al. (2023). Pre-eclampsia. Nat Rev Dis Primers. 9(1): 8. https://doi.org/10.1038/s41572-023-00417-6; PMid:36797292

8. Dines V, Suvakov S, Kattah A, Vermunt J, Narang K, Jayachandran M et al. (2023). Preeclampsia and the Kidney: Pathophysiology and Clinical Implications. Compr Physiol. 13(1): 4231-4267. https://doi.org/10.1002/j.2040-4603.2023.tb00249.x; PMid:36715282

9. Farina A, Rapacchia G, Freni Sterrantino A, Pula G, Morano D, Rizzo N. (2011). Prospective evaluation of ultrasound and biochemical-based multivariable models for the prediction of late pre-eclampsia. Prenat Diagn. 31(12): 1147-1152. https://doi.org/10.1002/pd.2849; PMid:22009522

10. Fetal Medicine Foundation. Risk for preeclampsia. URL: https://fetalmedicine.org/research/assess/preeclampsia/first-trimester.

11. Frost A, Agarwal M, Leeson P. (2025). International guidelines for the management of hypertensive disorders of pregnancy: an opportunity to improve the lifelong health of women? Eur J Prev Cardiol. 32(1): zwaf488. https://doi.org/10.1093/eurjpc/zwaf488; PMid:40794599

12. Huppertz B. (2018). The Critical Role of Abnormal Trophoblast Development in the Etiology of Preeclampsia. Curr Pharm Biotechnol. 19(10): 771-780. https://doi.org/10.2174/1389201019666180427110547; PMid:29701150 PMCid:PMC6463401

13. Ives CW, Sinkey R, Rajapreyar I, Tita ATN, Oparil S. (2020). Preeclampsia-Pathophysiology and Clinical Presentations: JACC State-of-the-Art Review. J Am Coll Cardiol. 76(14): 1690-1702. https://doi.org/10.1016/j.jacc.2020.08.014; PMid:33004135 PMCid:PMC12042644

14. Javandoust Gharehbagh F, Soltani-Zangbar MS, Yousefzadeh Y. (2024). Immunological mechanisms in preeclampsia: A narrative review. J Reprod Immunol. 164: 104282. https://doi.org/10.1016/j.jri.2024.104282; PMid:38901108

15. Liu J, Chen Y, Tai ST, Nguyen-Hoang L, Li K, Lin J et al. (2024). First Trimester Preeclampsia Screening and Prevention: Perspective in Chinese Mainland. Maternal Fetal Med. 6(2): 84-91. https://doi.org/10.1097/FM9.0000000000000215; PMid:40432929 PMCid:PMC12106214

16. Magee LA, Brown MA, Hall DR, Gupte S, Hennessy A, Karumanchi SA et al. (2022, Mar). The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 27: 148-169. Epub 2021 Oct 9. https://doi.org/10.1016/j.preghy.2021.09.008; PMid:35066406 PMCid:PMC11190647

17. Ministry of Health of Ukraine. (2022). Hipertenzyvni rozlady pid chas vahitnosti, polohiv ta u pisliapolohovomu periodi. Nakaz MOZ Ukrainy vid 24.01.2022. No. 151.

18. Ministry of Health of Ukraine. (2023). Zatrymka rostu ploda. Nakaz MOZ Ukrainy vid 02.10.2023 No. 1718.

19. National Institute for Health and Care Excellence. (2019). Hypertension in pregnancy: diagnosis and management. NICE guideline [NG133]. London: NICE (updated 2023).

20. Ninan N, Ali R, Morfaw F, McDonald SD. (2023). Prevention of pre-eclampsia with aspirin: a systematic review of guidelines and evaluation of the quality of recommendation evidence. Int J Gynaecol Obstet. 161(1): 26-39. https://doi.org/10.1002/ijgo.14471; PMid:36129381

21. Oliveira N, Magder LS, Blitzer MG, Baschat AA. (2014). First-trimester prediction of pre-eclampsia: external validity of algorithms in a prospectively enrolled cohort. Ultrasound Obstet Gynecol. 44(3): 279-285. https://doi.org/10.1002/uog.13435; PMid:24913190

22. Parra-Cordero M, Bennasar M, Martinez JM, Eixarch E, Torres X, Gratacos E. (2013). Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy. Ultrasound Obstet Gynecol. 41(5): 538-544. https://doi.org/10.1002/uog.12264; PMid:22807133

23. Phipps EA, Thadhani R, Benzing T, Karumanchi SA. (2019). Pre-eclampsia: pathogenesis and diagnostics. Nat Rev Nephrol. 5(5): 275-289. https://doi.org/10.1038/s41581-019-0119-6; PMid:30792480 PMCid:PMC6472952

24. Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. (2009). First-trimester prediction of hypertensive disorders in pregnancy. Hypertension. 53(5): 812-818. https://doi.org/10.1161/HYPERTENSIONAHA.108.127977; PMid:19273739

25. Poon LC, Magee LA, Verlohren S, Shennan A, von Dadelszen P, Sheiner E et al. (2021). A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: compiled by the Pregnancy and Non-Communicable Diseases Committee of FIGO. Int J Gynaecol Obstet. 154; Suppl 1: 3-31. https://doi.org/10.1002/ijgo.13763; PMid:34327714 PMCid:PMC9290930

26. Poon LC, Nicolaides KH. (2014). Early prediction of preeclampsia. Obstet Gynecol Int. 2014: 297397. Epub 2014 Jul 17. https://doi.org/10.1155/2014/297397; PMid:25136369 PMCid:PMC4127237

27. Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H et al. (2019, May). The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 145; Suppl 1: 1-33. doi: 10.1002/ijgo.12802. Erratum in: Int J Gynaecol Obstet. 2019 Sep; 146(3): 390-391. PMID: 31111484; PMCID: PMC6944283. https://doi.org/10.1002/ijgo.12892

28. Redman CW, Staff AC. (2015, Oct). Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am J Obstet Gynecol. 213; 4 Suppl: S9.e1, S9-11. https://doi.org/10.1016/j.ajog.2015.08.003; PMid:26428507

29. Roberts JM, Hubel CA. (2009, Mar). The two stage model of preeclampsia: variations on the theme. Placenta. 30; Suppl A: S32-37. Epub 2008 Dec 13. https://doi.org/10.1016/j.placenta.2008.11.009; PMid:19070896 PMCid:PMC2680383

30. Rolnik DL, Wright D, Poon LC et al. (2017, Aug 17). Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 377(7): 613-622. Epub 2017 Jun 28. https://doi.org/10.1056/NEJMoa1704559; PMid:28657417

31. Romero R, Jung E, Chaiworapongsa T, Erez O, Gudicha DW, Kim YM et al. (2022). Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology. Am J Obstet Gynecol. 227(4): 615.e1-615.e25. https://doi.org/10.1016/j.ajog.2022.04.015; PMid:36180175 PMCid:PMC9525890

32. Sotiriadis A, Hernandez-Andrade E, da Silva Costa F, Ghi T, Glanc P, Khalil A et al. (2019). ISUOG Practice Guidelines: role of ultrasound in screening for and follow-up of pre-eclampsia. Ultrasound Obstet Gynecol. 53(1): 7-22. https://doi.org/10.1002/uog.20105; PMid:30320479 PMCid:PMC10183917

33. Staff AC. (2019, Sep). The two-stage placental model of preeclampsia: An update. J Reprod Immunol. 134-135: 1-10. Epub 2019 Jul 8. https://doi.org/10.1016/j.jri.2019.07.004; PMid:31301487 PMCid:PMC12042644

34. Stampalija T, Lees C, Ghi T, Cornette J, Gyselaers W, Ferrazzi E et al. (2025). ISUOG Consensus Statement on maternal hemodynamic assessment in hypertensive disorders of pregnancy and fetal growth restriction. Ultrasound Obstet Gynecol. 66(5): 681-696. https://doi.org/10.1002/uog.70040; PMid:40997762 PMCid:PMC12579779

35. Stepan H, Galindo A, Hund M, Schlembach D, Sillman J et al. (2023). Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction. Ultrasound Obstet Gynecol. 61(2): 168-180. https://doi.org/10.1002/uog.26032; PMid:35816445

36. Velegrakis A, Kouvidi E, Fragkiadaki P, Sifakis S. (2023). Predictive value of the sFlt 1/PlGF ratio in women with suspected preeclampsia: An update (Review). Int J Mol Med. 52: 89. https://doi.org/10.3892/ijmm.2023.5292; PMid:37594116 PMCid:PMC10500221

37. Wright D, Tan MY, O'Gorman N, Poon LC et al. (2019, Feb). Predictive performance of the competing risk model in screening for preeclampsia. Am J Obstet Gynecol. 220(2): 199.e1-199.e13. Epub 2018 Nov 14. doi: 10.1016/j.ajog.2018.11.1087. Erratum in: Am J Obstet Gynecol. 2019 Nov; 221(5): 504. PMID: 30447210. https://doi.org/10.1016/j.ajog.2019.04.008

38. Yagel S, Cohen SM, Admati I, Skarbianskis N, Solt I, Zeisel A et al. (2023). Expert review: preeclampsia Type I and Type II. Am J Obstet Gynecol MFM. 5(12): 101203. https://doi.org/10.1016/j.ajogmf.2023.101203; PMid:37871693